Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study

MT Newswires Live06-23

Takeda Pharmaceutical's (TAK) Canadian unit, Takeda Canada, said Tuesday that its investigational oral tyrosine kinase 2 inhibitor zasocitinib showed "statistical superiority" over deucravacitinib for the primary and key secondary endpoints in a phase 3 study in adults with moderate-to-severe plaque psoriasis.

The company said more than 35% of patients receiving zasocitinib achieved complete skin clearance, or PASI 100, at week 16, more than 2.5 times the response rate for deucravacitinib.

Takeda Canada said the safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified.

The company said it plans to submit a new drug application for plaque psoriasis to the US Food and Drug Administration during the current fiscal year.

Shares of Takeda Pharmaceutical were up 1.3% in Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645839257?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645839257","market":"fut","top_or_hot":-1,"title":"Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical's (TAK) Canadian unit, Takeda Canada, said Tuesday that its investigational oral tyrosine kinase 2 inhibitor zasocitinib showed \"statistical superiority\" over deucravacitinib for the primary and key secondary endpoints in a phase 3 study in adults with moderate-to-severe plaque psoriasis.</p><p>The company said more than 35% of patients receiving zasocitinib achieved complete skin clearance, or PASI 100, at week 16, more than 2.5 times the response rate for deucravacitinib.</p><p>Takeda Canada said the safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified.</p><p>The company said it plans to submit a new drug application for plaque psoriasis to the US Food and Drug Administration during the current fiscal year.</p><p>Shares of Takeda Pharmaceutical were up 1.3% in Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Canada Says Zasocitinib Shows Superiority to Deucravacitinib in Phase 3 Psoriasis Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-23 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical's (TAK) Canadian unit, Takeda Canada, said Tuesday that its investigational oral tyrosine kinase 2 inhibitor zasocitinib showed \"statistical superiority\" over deucravacitinib for the primary and key secondary endpoints in a phase 3 study in adults with moderate-to-severe plaque psoriasis.</p><p>The company said more than 35% of patients receiving zasocitinib achieved complete skin clearance, or PASI 100, at week 16, more than 2.5 times the response rate for deucravacitinib.</p><p>Takeda Canada said the safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified.</p><p>The company said it plans to submit a new drug application for plaque psoriasis to the US Food and Drug Administration during the current fiscal year.</p><p>Shares of Takeda Pharmaceutical were up 1.3% in Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TAK","symbol_name":"武田制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645839257","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645839257","pubTimestamp":1782219674,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical's (TAK) Canadian unit, Takeda Canada, said Tuesday that its investigational oral tyrosine kinase 2 inhibitor zasocitinib showed \"statistical superiority\" over deucravacitinib for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TAK":"武田制药","BK4007":"制药"},"translate_title":"武田加拿大称Zasocitinib在银屑病3期研究中显示出优于Deucravacitinib","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TAK":1},"content_text":"Takeda Pharmaceutical's (TAK) Canadian unit, Takeda Canada, said Tuesday that its investigational oral tyrosine kinase 2 inhibitor zasocitinib showed \"statistical superiority\" over deucravacitinib for the primary and key secondary endpoints in a phase 3 study in adults with moderate-to-severe plaque psoriasis.The company said more than 35% of patients receiving zasocitinib achieved complete skin clearance, or PASI 100, at week 16, more than 2.5 times the response rate for deucravacitinib.Takeda Canada said the safety profile of zasocitinib was consistent with previous studies, with no new safety signals identified.The company said it plans to submit a new drug application for plaque psoriasis to the US Food and Drug Administration during the current fiscal year.Shares of Takeda Pharmaceutical were up 1.3% in Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645839257","isCrawlerRequest":true}